KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to -$26.5 million.

  • Novavax's Change in Accured Expenses fell 213.76% to -$26.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$343.5 million, marking a year-over-year increase of 7.84%. This contributed to the annual value of -$385.6 million for FY2024, which is 1.80% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Change in Accured Expenses is -$26.5 million, which was up 57.64% from -$62.6 million recorded in Q2 2025.
  • Novavax's 5-year Change in Accured Expenses high stood at $823.0 million for Q4 2022, and its period low was -$272.5 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$62.6 million (2025), whereas its average is -$96.9 million.
  • Per our database at Business Quant, Novavax's Change in Accured Expenses soared by 731.07% in 2021 and then crashed by 316.60% in 2022.
  • Over the past 5 years, Novavax's Change in Accured Expenses (Quarterly) stood at $419.6 million in 2021, then surged by 96.13% to $823.0 million in 2022, then tumbled by 103.59% to -$29.5 million in 2023, then slumped by 43.74% to -$42.5 million in 2024, then slumped by 213.76% to -$26.5 million in 2025.
  • Its Change in Accured Expenses stands at -$26.5 million for Q3 2025, versus -$62.6 million for Q2 2025 and -$211.8 million for Q1 2025.